These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19375624)

  • 1. Current prostate cancer treatments: effect on quality of life.
    Gomella LG; Johannes J; Trabulsi EJ
    Urology; 2009 May; 73(5 Suppl):S28-35. PubMed ID: 19375624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M; Walker-Corkery E; Barry MJ
    J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in patients with localized prostate cancer.
    Quek ML; Penson DF
    Urol Oncol; 2005; 23(3):208-15. PubMed ID: 15907723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data.
    Stokes ME; Black L; Benedict A; Roehrborn CG; Albertsen P
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):278-84. PubMed ID: 20212521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy].
    Adolfsson J
    Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population.
    Sennfält K; Carlsson P; Thorfinn J; Frisk J; Henriksson M; Varenhorst E
    Scand J Urol Nephrol; 2003; 37(3):226-31. PubMed ID: 12775282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life after therapy for localized prostate cancer.
    Penson DF
    Cancer J; 2007; 13(5):318-26. PubMed ID: 17921731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic and organizational aspects in the management of prostate cancer.
    Cellini N; Luzi S; Morganti AG; Mattiucci GC; Smaniotto D; Racioppi M
    Rays; 1999; 24(3):460-71. PubMed ID: 10605307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostatic cancer: an expensive dilemma].
    Borre M; Nerstrøm B; Overgaard J
    Ugeskr Laeger; 1997 Apr; 159(17):2534-7. PubMed ID: 9182381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
    Mold JW; Holtgrave DR; Bisonni RS; Marley DS; Wright RA; Spann SJ
    J Fam Pract; 1992 May; 34(5):561-8. PubMed ID: 1578205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative cost pattern comparison of prostate cancer treatments.
    Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
    Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A time tradeoff method for eliciting partner's quality of life due to patient's health states in prostate cancer.
    Basu A; Dale W; Elstein A; Meltzer D
    Med Decis Making; 2010; 30(3):355-65. PubMed ID: 20228288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients.
    Kang SH; Kim JW; Bae JH; Park HS; Moon DG; Yoon DK; Cheon J; Kim JJ
    Asian J Androl; 2006 Sep; 8(5):629-36. PubMed ID: 16847531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of information on preference heterogeneity and individualized care.
    Basu A; Meltzer D
    Med Decis Making; 2007; 27(2):112-27. PubMed ID: 17409362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
    Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
    CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
    Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
    BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention.
    Giesler RB; Given B; Given CW; Rawl S; Monahan P; Burns D; Azzouz F; Reuille KM; Weinrich S; Koch M; Champion V
    Cancer; 2005 Aug; 104(4):752-62. PubMed ID: 15986401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.